Molecular Imaging Detects HER2-Positive Breast Cancer Changes After Two Cycles
Molecular imaging using 68Ga-HER2 PET/CT can detect changes in HER2-positive breast cancer after just two cycles of neoadjuvant treatment, offering physicians an early measure of therapeutic response, according to research published in the October issue of The Journal of Nuclear Medicine. The prospective study evaluates the imaging modality’s ability to track tumor modifications prior to surgery in aggressive cancer cases.
HER2-Positive Breast Cancer Challenges Clinical Monitoring
HER2-positive tumors account for 20% to 25% of all breast cancer cases, carrying a reputation for aggressive behavior and poorer patient outcomes. Clinicians typically administer neoadjuvant therapy before surgery to shrink these masses, yet monitoring tools provide limited early insight into whether a patient responds to the regimen. Baseline scans in the research demonstrated a soft-tissue lesion measuring approximately 2.3 by 2.2 centimeters in the upper outer quadrant of the left breast, showing marked radiotracer uptake with a maximum standardized uptake value (SUVmax) of 10.1.
Traditional diagnostic modalities present distinct trade-offs between accuracy and timeliness. Ultrasound offers cost-effective assessment of lymph nodes but is operator-dependent; mammography detects calcifications well but poorly measures tumor size; MRI, the standard neoadjuvant therapy monitoring modality, faces challenges in differentiating between fibrosis and tumors; and clinical examination, although rapid, lacks accuracy,
said Yunjiang Liu, MD, PhD, professor at the Fourth Hospital of Hebei Medical University and Hebei Provincial Tumor Hospital in Shijiazhuang, China. This trade-off between accuracy and timeliness drives the need for novel approaches.
Imaging Progression Across Treatment Cycles
To overcome diagnostic gaps, researchers evaluated 68Ga-HER2 PET/CT as a noninvasive, whole-body method for visualizing HER2 expression. Imaging at the end of the second treatment cycle revealed a residual lesion measuring approximately 2.2 by 1.0 centimeters in the same region, accompanied by the absence of abnormal radiotracer accumulation. Preoperative imaging demonstrated a further reduction in lesion size to approximately 2.0 by 0.6 centimeters, maintaining no detected abnormal tracer uptake.
Common Questions About 68Ga-HER2 PET/CT Monitoring
What percentage of breast cancer cases are HER2-positive?
HER2-positive tumors represent 20% to 25% of all breast cancer cases. These aggressive tumors are frequently treated with neoadjuvant therapy prior to surgical intervention.
How early can 68Ga-HER2 PET/CT detect changes in HER2-positive tumors?
Research published in The Journal of Nuclear Medicine shows that 68Ga-HER2 PET/CT detects changes in HER2-positive breast cancer after only two cycles of neoadjuvant treatment. This early detection helps physicians gather information to support earlier discussions about subsequent treatment and surgical planning.
Where was the clinical evaluation of 68Ga-HER2 PET/CT conducted?
The research on 68Ga-HER2 PET/CT for monitoring neoadjuvant therapy involved work associated with Yunjiang Liu, MD, PhD, a professor at the Fourth Hospital of Hebei Medical University and Hebei Provincial Tumor Hospital in Shijiazhuang, China.
Baseline assessments recorded a soft-tissue lesion with an SUVmax of 10.1 before therapy initiation.
Related reading